Loading...
XNASMLAB
Market cap729mUSD
Jan 10, Last price  
134.39USD
1D
-5.38%
1Q
6.51%
Jan 2017
9.48%
Name

Mesa Laboratories Inc

Chart & Performance

D1W1MN
XNAS:MLAB chart
P/E
P/S
3.38
EPS
Div Yield, %
0.47%
Shrs. gr., 5y
5.96%
Rev. gr., 5y
15.95%
Revenues
216m
-1.32%
10,041,00011,583,00017,242,00019,558,00021,536,00021,929,00032,826,00039,616,00046,435,00052,724,00071,330,00084,659,00093,665,00096,179,000103,135,000117,687,000133,937,000184,335,000219,080,000216,187,000
Net income
-254m
L
2,312,0002,805,0003,958,0004,610,0004,790,0004,769,0006,183,0007,919,0008,450,0009,000,0009,583,00011,169,00011,183,000-2,962,0007,484,0001,349,0003,274,0001,871,000930,000-254,246,000
CFO
44m
+57.71%
2,501,0002,306,0004,032,0004,616,0005,075,0005,980,0008,873,00012,489,00011,402,00012,373,00010,816,00016,903,0007,750,00024,814,00030,554,00026,559,00037,073,00039,223,00027,983,00044,133,000
Dividend
Nov 29, 20240 USD/sh
Earnings
Feb 03, 2025

Profile

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
IPO date
Feb 29, 1984
Employees
698
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
216,187
-1.32%
219,080
18.85%
184,335
37.63%
Cost of revenue
213,729
215,760
179,633
Unusual Expense (Income)
NOPBT
2,458
3,320
4,702
NOPBT Margin
1.14%
1.52%
2.55%
Operating Taxes
(21,402)
(1,319)
1,703
Tax Rate
36.22%
NOPAT
23,860
4,639
2,999
Net income
(254,246)
-27,438.28%
930
-50.29%
1,871
-42.85%
Dividends
(3,447)
(3,406)
(3,339)
Dividend yield
0.58%
0.36%
0.25%
Proceeds from repurchase of equity
6,078
6,277
BB yield
-0.65%
-0.46%
Debt
Debt current
2,986
8,022
2,768
Long-term debt
231,297
186,140
221,133
Deferred revenue
Other long-term liabilities
9,000
7,693
7,924
Net debt
206,069
161,252
174,555
Cash flow
Cash from operating activities
44,133
27,983
39,223
CAPEX
(2,567)
(4,544)
(4,432)
Cash from investing activities
(81,306)
(9,494)
(305,225)
Cash from financing activities
32,836
(33,328)
52,576
FCF
23,634
46,136
(56,589)
Balance
Cash
28,214
32,910
49,346
Long term investments
Excess cash
17,405
21,956
40,129
Stockholders' equity
145,393
393,480
393,801
Invested Capital
368,285
565,357
574,765
ROIC
5.11%
0.81%
0.54%
ROCE
0.61%
0.53%
0.72%
EV
Common stock shares outstanding
5,386
5,361
5,335
Price
109.73
-37.20%
174.73
-31.45%
254.88
4.67%
Market cap
591,006
-36.91%
936,728
-31.11%
1,359,785
8.98%
EV
797,075
1,097,980
1,534,340
EBITDA
34,032
37,144
29,770
EV/EBITDA
23.42
29.56
51.54
Interest
5,697
3,709
3,885
Interest/NOPBT
231.77%
111.72%
82.62%